Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Advances in Detective, Predictive, and Prognostic Biomarkers and Metabolism of...
share announcement

Advances in Detective, Predictive, and Prognostic Biomarkers and Metabolism of Pancreas and Liver Cancer

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 2619

Special Issue Editor

Prof. Dr. Shiro Urayama

E-Mail Website
Guest Editor
UC Davis Medical Center, Sacramento, CA 95817, USA
Interests: pancreatic cancer biomarker; metabolomic/metabolic biomarker; diagnostic and therapeutic development; translational science

Special Issue Information

Dear Colleagues,

Pancreas cancer is a malignant tumor that is notorious for being a difficult tumor to detect at an intervenable stage and treat, having the worst prognosis among human cancers. Liver cancer has an association with advancing age and sequelae of chronic hepatic inflammatory/infectious diseases. As the global aging population continues to expand, these cancers are expected to become two of the highest mortality rate cancers in the coming decade, in stark contrast to other major malignancies.

To overcome the current status of the cancers, various molecular, as well as computational, approaches are being applied in elucidating features of the cancer development, progression, and response to therapeutics. Increasingly, the unique metabolisms of the pancreas and liver malignancies are being identified and incorporated in exploring the diagnostic and therapeutic approaches. In order to improve the poor prognosis of the disease, early detection biomarkers are much needed with which we may be able to select a subpopulation who would benefit from more intensive screening strategies or be directed to selective therapies. In addition, as more targeted and novel immunological therapeutics become available, biomarker applications to pancreas and liver cancers such as predicting therapeutic response and overall prognosis would be highly desirable. In this setting, we invite original research as well as review and viewpoint manuscripts for this Special Issue, contributing to the updated knowledge and future directions in metabolism and biomarkers in pancreas and liver cancer.

Prof. Dr. Shiro Urayama
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pancreatic cancer
  • Liver cancer
  • Cancer metabolism
  • Biomarkers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 1879 KiB  
Review
Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer
by Debra Rivera
Metabolites 2022, 12(5), 409; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo12050409 - 30 Apr 2022
Cited by 2 | Viewed by 2157
Abstract
Advances in magnet technologies have led to next generation 7T magnetic resonance scanners which can fit in the footprint and price point of conventional hospital scanners (1.5–3T). It is therefore worth asking if there is a role for 7T magnetic resonance imaging and [...] Read more.
Advances in magnet technologies have led to next generation 7T magnetic resonance scanners which can fit in the footprint and price point of conventional hospital scanners (1.5–3T). It is therefore worth asking if there is a role for 7T magnetic resonance imaging and spectroscopy for the treatment of solid tumor cancers. Herein, we survey the medical literature to evaluate the unmet clinical needs for patients with pancreatic and hepatic cancer, and the potential of ultra-high field proton imaging and phosphorus spectroscopy to fulfil those needs. We draw on clinical literature, preclinical data, nuclear magnetic resonance spectroscopic data of human derived samples, and the efforts to date with 7T imaging and phosphorus spectroscopy. At 7T, the imaging capabilities approach histological resolution. The spectral and spatial resolution enhancements at high field for phospholipid spectroscopy have the potential to reduce the number of exploratory surgeries due to tumor boundaries undefined at conventional field strengths. Phosphorus metabolic imaging at 7T magnetic field strength, is already a mainstay in preclinical models for molecular phenotyping, energetic status evaluation, dosimetry, and assessing treatment response for both pancreatic and liver cancers. Metabolic imaging of primary tumors and lymph nodes may provide powerful metrics to aid staging and treatment response. As tumor tissues contain extreme levels of phospholipid metabolites compared to the background signal, even spectroscopic volumes containing less than 50% tumor can be detected and/or monitored. Phosphorus spectroscopy allows non-invasive pH measurements, indicating hypoxia, as a predictor of patients likely to recur. We conclude that 7T multiparametric approaches that include metabolic imaging with phosphorus spectroscopy have the potential to meet the unmet needs of non-invasive location-specific treatment monitoring, lymph node staging, and the reduction in unnecessary surgeries for patients undergoing resections for pancreatic cancer. There is also potential for the use of 7T phosphorous spectra for the phenotyping of tumor subtypes and even early diagnosis (<2 mL). Whether or not 7T can be used for all patients within the next decade, the technology is likely to speed up the translation of new therapeutics. Full article
(This article belongs to the Special Issue Advances in Detective, Predictive, and Prognostic Biomarkers and Metabolism of Pancreas and Liver Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop